First Time Loading...

Arbutus Biopharma Corp
NASDAQ:ABUS

Watchlist Manager
Arbutus Biopharma Corp Logo
Arbutus Biopharma Corp
NASDAQ:ABUS
Watchlist
Price: 2.73 USD -1.8% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

ABUS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Arbutus Biopharma Corp. is a biopharmaceutical company. [ Read More ]

The intrinsic value of one ABUS stock under the Base Case scenario is 0.82 USD. Compared to the current market price of 2.73 USD, Arbutus Biopharma Corp is Overvalued by 70%.

Key Points:
ABUS Intrinsic Value
Base Case
0.82 USD
Overvaluation 70%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Arbutus Biopharma Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ABUS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Arbutus Biopharma Corp

Provide an overview of the primary business activities
of Arbutus Biopharma Corp.

What unique competitive advantages
does Arbutus Biopharma Corp hold over its rivals?

What risks and challenges
does Arbutus Biopharma Corp face in the near future?

Has there been any significant insider trading activity
in Arbutus Biopharma Corp recently?

Summarize the latest earnings call
of Arbutus Biopharma Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Arbutus Biopharma Corp.

Provide P/S
for Arbutus Biopharma Corp.

Provide P/E
for Arbutus Biopharma Corp.

Provide P/OCF
for Arbutus Biopharma Corp.

Provide P/FCFE
for Arbutus Biopharma Corp.

Provide P/B
for Arbutus Biopharma Corp.

Provide EV/S
for Arbutus Biopharma Corp.

Provide EV/GP
for Arbutus Biopharma Corp.

Provide EV/EBITDA
for Arbutus Biopharma Corp.

Provide EV/EBIT
for Arbutus Biopharma Corp.

Provide EV/OCF
for Arbutus Biopharma Corp.

Provide EV/FCFF
for Arbutus Biopharma Corp.

Provide EV/IC
for Arbutus Biopharma Corp.

Show me price targets
for Arbutus Biopharma Corp made by professional analysts.

What are the Revenue projections
for Arbutus Biopharma Corp?

How accurate were the past Revenue estimates
for Arbutus Biopharma Corp?

What are the Net Income projections
for Arbutus Biopharma Corp?

How accurate were the past Net Income estimates
for Arbutus Biopharma Corp?

What are the EPS projections
for Arbutus Biopharma Corp?

How accurate were the past EPS estimates
for Arbutus Biopharma Corp?

What are the EBIT projections
for Arbutus Biopharma Corp?

How accurate were the past EBIT estimates
for Arbutus Biopharma Corp?

Compare the revenue forecasts
for Arbutus Biopharma Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Arbutus Biopharma Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Arbutus Biopharma Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Arbutus Biopharma Corp compared to its peers.

Compare the P/E ratios
of Arbutus Biopharma Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Arbutus Biopharma Corp with its peers.

Analyze the financial leverage
of Arbutus Biopharma Corp compared to its main competitors.

Show all profitability ratios
for Arbutus Biopharma Corp.

Provide ROE
for Arbutus Biopharma Corp.

Provide ROA
for Arbutus Biopharma Corp.

Provide ROIC
for Arbutus Biopharma Corp.

Provide ROCE
for Arbutus Biopharma Corp.

Provide Gross Margin
for Arbutus Biopharma Corp.

Provide Operating Margin
for Arbutus Biopharma Corp.

Provide Net Margin
for Arbutus Biopharma Corp.

Provide FCF Margin
for Arbutus Biopharma Corp.

Show all solvency ratios
for Arbutus Biopharma Corp.

Provide D/E Ratio
for Arbutus Biopharma Corp.

Provide D/A Ratio
for Arbutus Biopharma Corp.

Provide Interest Coverage Ratio
for Arbutus Biopharma Corp.

Provide Altman Z-Score Ratio
for Arbutus Biopharma Corp.

Provide Quick Ratio
for Arbutus Biopharma Corp.

Provide Current Ratio
for Arbutus Biopharma Corp.

Provide Cash Ratio
for Arbutus Biopharma Corp.

What is the historical Revenue growth
over the last 5 years for Arbutus Biopharma Corp?

What is the historical Net Income growth
over the last 5 years for Arbutus Biopharma Corp?

What is the current Free Cash Flow
of Arbutus Biopharma Corp?

Financials

Balance Sheet Decomposition
Arbutus Biopharma Corp

Current Assets 132m
Cash & Short-Term Investments 126m
Receivables 1.8m
Other Current Assets 4.2m
Non-Current Assets 12.4m
Long-Term Investments 6.3m
PP&E 6.1m
Current Liabilities 22.5m
Accounts Payable 3.2m
Accrued Liabilities 7.5m
Other Current Liabilities 11.8m
Non-Current Liabilities 15.9m
Other Non-Current Liabilities 15.9m
Efficiency

Earnings Waterfall
Arbutus Biopharma Corp

Revenue
18.1m USD
Operating Expenses
-96.2m USD
Operating Income
-78.1m USD
Other Expenses
5.3m USD
Net Income
-72.8m USD

Free Cash Flow Analysis
Arbutus Biopharma Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ABUS Profitability Score
Profitability Due Diligence

Arbutus Biopharma Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
ROE is Increasing
ROIC is Increasing
Negative Revenue Growth Forecast
23/100
Profitability
Score

Arbutus Biopharma Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

ABUS Solvency Score
Solvency Due Diligence

Arbutus Biopharma Corp's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
60/100
Solvency
Score

Arbutus Biopharma Corp's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ABUS Price Targets Summary
Arbutus Biopharma Corp

Wall Street analysts forecast ABUS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABUS is 4.49 USD with a low forecast of 4.04 USD and a high forecast of 5.25 USD.

Lowest
Price Target
4.04 USD
48% Upside
Average
Price Target
4.49 USD
64% Upside
Highest
Price Target
5.25 USD
92% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ABUS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ABUS Price
Arbutus Biopharma Corp

1M 1M
+10%
6M 6M
+56%
1Y 1Y
-9%
3Y 3Y
-10%
5Y 5Y
-13%
10Y 10Y
-81%
Annual Price Range
2.73
52w Low
1.69
52w High
3.12
Price Metrics
Average Annual Return -4.37%
Standard Deviation of Annual Returns 29.19%
Max Drawdown -73%
Shares Statistics
Market Capitalization 463.7m USD
Shares Outstanding 180 175 008
Percentage of Shares Shorted 3.3%

ABUS Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Arbutus Biopharma Corp Logo
Arbutus Biopharma Corp

Country

United States of America

Industry

Biotechnology

Market Cap

463.7m USD

Dividend Yield

0%

Description

Arbutus Biopharma Corp. is a biopharmaceutical company. The company is headquartered in Warminster, Pennsylvania and currently employs 85 full-time employees. The company went IPO on 2010-11-13. The firm is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The firm is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).

Contact

PENNSYLVANIA
Warminster
701 Veterans Circle
+16044193200.0
http://www.arbutusbio.com/

IPO

2010-11-13

Employees

85

Officers

Co-Founder, Interim President, CEO & Director
Mr. Michael J. McElhaugh
Chief Scientific Officer
Dr. Michael J. Sofia Ph.D.
CFO & Chief Accounting Officer
Mr. David C. Hastings CPA
Vice President of Investor Relations
Ms. Lisa M. Caperelli
General Counsel & Chief Compliance Officer
Mr. J. Christopher Naftzger BA, Esq., J.D.
Vice President of Human Resources
Ms. Shannon Briscoe SPHR
Show More
Chief Medical Officer
Dr. Karen Sims M.D., Ph.D.
Secretary
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.
Show Less

See Also

Discover More
What is the Intrinsic Value of one ABUS stock?

The intrinsic value of one ABUS stock under the Base Case scenario is 0.82 USD.

Is ABUS stock undervalued or overvalued?

Compared to the current market price of 2.73 USD, Arbutus Biopharma Corp is Overvalued by 70%.